Trial Profile
NON-INTERVENTIONAL STUDY TO ASSESS THE HEALTH-RELATED QUALITY OF LIFE IN SEVERE OR MODERATELY SEVERE HEMOPHILIA A SUBJECTS TREATED WITH REFACTO AF ROUTINE PROPHYLAXIS
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Moroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 Nov 2020 Planned End Date changed from 1 May 2021 to 1 Jan 2022.
- 12 Nov 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Aug 2019 Planned initiation date changed from 1 Aug 2019 to 1 Sep 2019.